Susquehanna Fundamental Investments’s AC Immune ACIU Stock Holding History

Susquehanna Fundamental Investments’s Portfolio ACIU Stock Details ACIU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$99K	Sell	24,717 -1,800	-7%	-$7.79K	﹤0.01%	1452
2021 Q4	$131K	Sell	26,517 -30,909	-54%	-$180K	﹤0.01%	1305
2021 Q3	$385K	Buy	57,426 +31,616	+122%	+$226K	0.01%	1314
2021 Q2	$205K	Sell	25,810 -27,978	-52%	-$193K	﹤0.01%	1475
2021 Q1	$409K	Sell	53,788 -18,800	-26%	-$134K	0.01%	1208
2020 Q4	$375K	Buy	72,588 +19,210	+36%	+$98K	0.01%	1197
2020 Q3	$260K	Buy	+53,378	New	+$383K	0.01%	1112

Other funds holding ACIU

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Susquehanna Fundamental Investments's ACIU Position: Q1 2022 in Review

Susquehanna Fundamental Investments reduced its AC Immune (ACIU) stake by 6.8% in Q1 2022, selling an estimated $7.79K and leaving 24,717 shares worth $99K. The position accounts for ﹤0.01% of the portfolio, ranked #1452.

Susquehanna Fundamental Investments first reported a position in ACIU in Q3 2020 and has held it in 7 quarters since. The position peaked at $409K in Q1 2021. 36 funds tracked by Wall St. Rank hold ACIU as of Q1 2022.

Susquehanna Fundamental Investments held 24,717 shares of AC Immune worth $99K as of Q1 2022.
Susquehanna Fundamental Investments sold 1,800 AC Immune shares in Q1 2022, an estimated $7.79K.
AC Immune made up ﹤0.01% of Susquehanna Fundamental Investments's portfolio in Q1 2022, its #1452 holding.
Susquehanna Fundamental Investments first reported a position in AC Immune in Q3 2020 and has held it in 7 quarters since.
Susquehanna Fundamental Investments's AC Immune position peaked at $409K in Q1 2021.
36 funds tracked by Wall St. Rank held AC Immune as of Q1 2022.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2022, filed 16 May 2022.